文献速递MDS 与骨髓增殖性肿瘤白血病血栓与止血

PARP抑制剂治疗患者中骨髓增生异常综合征与急性髓系白血病风险:随机对照试验安全性荟萃分析及WHO药物警戒数据库回顾性研究

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
PubMed 文献 · Lancet Haematol · 2020-12-18

该研究通过系统综述与安全性荟萃分析(28项RCT,5693例PARP抑制剂组,3406例对照组)及VigiBase药物警戒数据库回顾性分析,评估PARP抑制剂相关骨髓增生异常综合征(MDS)和急性髓系白血病(AML)风险。

要点

  • 该不良事件延迟且常致命,需特别关注一线维持治疗场景。

核心结论

  • PARP抑制剂较安慰剂治疗增加MDS和AML风险。
  • 此类延迟且常致命的不良事件需进一步研究以改善临床认识,尤其在一线维持治疗中。

研究设计与样本

  • 系统综述与安全性荟萃分析纳入28项RCT(18项安慰剂对照,10项非安慰剂对照),PARP抑制剂组5693例,对照组3406例。
  • 基于18项安慰剂对照RCT(7307例)进行固定效应荟萃分析,计算Peto OR及95%CI。
  • 回顾性药物警戒研究从VigiBase提取PARP抑制剂相关MDS/AML病例并总结临床特征。

主要发现

  • VigiBase提取178例PARP抑制剂相关MDS(99例)和AML(79例)病例。
  • 104例报告结局中47例(45%)死亡。

关键数值与推荐

  • 所有28项RCT的偏倚风险评级为不明确。
  • 主要结局为RCT中PARP抑制剂对比安慰剂的MDS/AML汇总风险。

临床怎么用

  • 使用PARP抑制剂时应警惕MDS/AML风险,尤其在一线维持治疗中。
  • 长期随访中注意延迟出现的MDS/AML,并关注治疗持续时间与潜伏期。

局限性

  • 所有纳入RCT偏倚风险评级为不明确。
  • VigiBase药物警戒数据存在报告偏倚及数据缺失可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some concerns have emerged regarding rare and delayed adverse events including cases of myelodysplastic syndrome and acute myeloid leukaemia, for which data are scarce. The aim of this study was to estimate the risk of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibitors, via a systematic review and safety meta-analysis, and to describe clinical features of PARP inhibitor-related myelodysplastic syndrome and acute myeloid leukaemia cases reported in WHO's pharmacovigilance database (VigiBase). METHODS: We systematically reviewed randomised controlled trials (RCTs) comparing PARP inhibitor therapy versus control treatments (placebo and non-placebo) in adults (age ≥18 years) treated for cancer in MEDLINE, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov registry with ongoing surveillance up to May 31, 2020. The date range for included studies was not restricted. By a stepwise method to capture all available adverse events, we first extracted data on myelodysplastic syndrome and acute myeloid leukaemia cases from ClinicalTrials.gov. If cases were not available, we extracted them from published manuscripts, or subsequently contacted corresponding authors or sponsors to provide data. RCTs without available data from ClinicalTrials.gov, publications, or corresponding authors or sponsors were excluded. The primary outcome was the summary risk of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibition versus placebo treatment in RCTs. We used a fixed-effects meta-analysis to obtain Peto odds ratios (ORs) with 95% CIs. In a separate observational, retrospective, cross-sectional pharmacovigilance study of VigiBase, cases of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibitor therapy were extracted on May 3, 2020, and clinical features summarised with a focus on median duration of PARP inhibitor exposure, median latency period between first drug exposure and diagnosis, and proportion of cases resulting in death. Our systematic review and safety meta-analysis were registered with PROSPERO, CRD42020175050. Our retrospective pharmacovigilance study was registered on ClinicalTrials.gov, NCT04326023. FINDINGS: For our safety meta-analysis, initial searches identified 1617 citations, and 31 RCTs were systematically reviewed for eligibility. 28 RCTs with available adverse events were analysed (18 placebo and ten non-placebo RCTs), with 5693 patients in PARP inhibitor groups and 3406 patients in control groups. Based on the 18 placebo RCTs (n=7307 patients), PARP inhibitors significantly increased the risk of myelodysplastic syndrome and acute myeloid leukaemia compared with placebo treatment (Peto OR 2·63 [95% CI 1·13-6·14], p=0·026) with no between-study heterogeneity (I2=0%, χ2 p=0·91). The incidence of myelodysplastic syndrome and acute myeloid leukaemia across PARP inhibitor groups was 0·73% (95% CI 0·50-1·07; I2=0%, χ2 p=0·87; 21 events out of 4533 patients) and across placebo groups was 0·47% (0·26-0·85; I2=0%, χ2 p=1·00; three events out of 2774 patients). All 28 RCTs were rated as having unclear risk of bias. In VigiBase, 178 cases of myelodysplastic syndrome (n=99) and acute myeloid leukaemia (n=79) related to PARP inhibitor therapy were extracted. In cases with available data, median treatment duration was 9·8 months (IQR 3·6-17·4; n=96) and median latency period since first exposure to a PARP inhibitor was 17·8 months (8·4-29·2; n=58). Of 104 cases that reported outcomes, 47 (45%) resulted in death. INTERPRETATION: PARP inhibitors increased the risk of myelodysplastic syndrome and acute myeloid leukaemia versus placebo treatment. These delayed and often lethal adverse events should be studied further to improve clinical understanding, particularly in the front-line maintenance setting. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Morice PM, Leary A, Dolladille C, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2020. PMID: 33347814. doi:10.1016/S2352-3026(20)30360-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。